Table 2.
Study name | RIVAL (44) | RIFLE-STEACS (35) | RIVAL-STEMI (45) | MATRIX (46) | SAFARI-PCI (48) |
---|---|---|---|---|---|
Study Design | Multicenter, 32 countries. 1:1 randomization; Open label |
Multicenter, European, 1:1 randomization; Open label. 4 high volume radial centers |
Multicenter, 32 countries, 1:1 randomized, open label. | Multicenter, European centers; 1:1 randomization; 0pen Label | Multicenter, 5 PCI centers in Canada. Randomized, open label. |
Population | 7,021 patients with ACS | 1,001 patients with STEMI | 1,958 patients with STEMI | 8,404 patients with ACS | 2,292 STEMI patients |
Study arms | Radial vs. Femoral | Radial vs. Femoral | Radial vs. Femoral | Radial vs. Femoral | Radial vs. Femoral |
Outcomes |
|
|
|
|
|
ACS, acute coronary syndrome; BARC, bleeding academic research consortium; CABG, coronary artery bypass graft surgery; CVA, cerebrovascular access; MATRIX, minimizing adverse haemorrhagic events by transradial access site and systemic implementation of AngioX; MI, myocardial infarction; RIFLE-STEACS, Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome; RIVAL, radial versus femoral access for coronary angiography and intervention in patients with acute coronary ssyndromes; SAFARI STEMI, safety and efficacy of femoral access vs radial access in ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; TFA, transfemoral access; TRA, transradial arterial access; TLR, target lesion revascularization.